Markets:

Overview

News

Currencies

International

Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

18.41 +0.53 (+2.96%)

Streaming Delayed Price Updated: 11:17 AM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗

March 09, 2026

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗

March 06, 2026

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

A Peek at Tango Therapeutics's Future Earnings ↗

November 03, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction ↗

November 04, 2025

Tango Therapeutics (TNGX) reported a strong Q3, beating revenue and EPS estimates. Despite the earnings beat, the stock saw mixed market reaction.

Via Chartmill

Topics Earnings

Insights into Tango Therapeutics's Upcoming Earnings ↗

May 09, 2025

Via Benzinga

Unveiling 5 Analyst Insights On Tango Therapeutics ↗

December 05, 2024

Via Benzinga

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗

October 31, 2025

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗

October 23, 2025

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Via Benzinga

Wondering what's happening in today's pre-market session? ↗

October 23, 2025

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Via Chartmill

Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy ↗

October 23, 2025

CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.

Via Stocktwits

The Analyst Landscape: 5 Takes On Tango Therapeutics ↗

November 11, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 23, 2025

Via Benzinga

Tango (TNGX) Q2 Revenue Drops 52% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress ↗

August 05, 2025

Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus.

Via Chartmill

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday ↗

June 06, 2025

Via Benzinga

What's going on in today's session ↗

June 03, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 29, 2025

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

May 19, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 19, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 06, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 10, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.